Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Insmed
Biotech
Insmed's shares double as lung disease med powers past phase 3
Insmed’s medicine didn’t just reduce exacerbations of a chronic lung disease in a phase 3 trial. It blew the primary endpoint out of the water.
Annalee Armstrong
May 28, 2024 10:32am
Insmed's inflammatory lung disease drug hits the mark in phase 2
Feb 3, 2020 10:57am
Former Insmed CMO Streck resurfaces at Alder
Jan 18, 2019 8:33am
Insmed CMO out the door, headed for 'West Coast'
Jan 15, 2019 7:28am
Insmed licenses AstraZeneca’s early-stage lung med in $150M-plus deal
Oct 5, 2016 8:18am
